Abstract
Background: Tuberculosis (TB) remains a global health catastrophe. Mycobacterium w is a heat-killed immune-modulating vaccine designed to attenuate the effects of TB, reduce time to sputum conversion, and thereby decrease transmission and improve cure rates.
Objectives: To evaluate Mycobacterium w (M w) immunotherapy as an adjunct to chemotherapy in participants with pulmonary TB (PTB).
Search strategy: In January 2012, we performed both a database search, a handsearch and corresponded with experts in the field.
Selection criteria: Randomised and quasi-randomised controlled trials of M w immunotherapy versus placebo (or no control) for participants with PTB.
Data collection and analysis: Two of the authors (SP and ZK) independently extracted data. Dichotomous outcomes were analysed using risk ratios (RR) and 95% confidence intervals (CI).
Outcomes: The primary outcome was to determine the effect of M w therapy on sputum conversion. Secondary outcomes were to determine the frequency of adverse reactions.
Main Results: Three trials (four papers) involving 368 participants were included. All four papers had methodological flaws. Overall, 173 participants received M w and 168 participants received placebo or no control. M w immunotherapy was effective at reducing time to sputum conversion at days 15 (RR 2.31; 95% CI 1.75 to 3.06; P < 0.001) and 30 (RR 1.83; 95% CI 1.12 to 2.98; P = 0.02). After day 30, benefit was only demonstrated in the category II TB (re-treatment).
Conclusions: The meta-analysis suggests benefit as regards the time to sputum conversion. The available data on M w immunotherapy for participants with PTB are however methodologically flawed. We advise that M w be investigated in a well-structured, randomised controlled trial.
Keywords: Tuberculosis, Mycobacterium w, immunotherapy.
Current Pharmaceutical Design
Title:Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review
Volume: 20 Issue: 39
Author(s): Shaheen Pandie, Mark E. Engel, Zita S. Kerbelker and Bongani M. Mayosi
Affiliation:
Keywords: Tuberculosis, Mycobacterium w, immunotherapy.
Abstract: Background: Tuberculosis (TB) remains a global health catastrophe. Mycobacterium w is a heat-killed immune-modulating vaccine designed to attenuate the effects of TB, reduce time to sputum conversion, and thereby decrease transmission and improve cure rates.
Objectives: To evaluate Mycobacterium w (M w) immunotherapy as an adjunct to chemotherapy in participants with pulmonary TB (PTB).
Search strategy: In January 2012, we performed both a database search, a handsearch and corresponded with experts in the field.
Selection criteria: Randomised and quasi-randomised controlled trials of M w immunotherapy versus placebo (or no control) for participants with PTB.
Data collection and analysis: Two of the authors (SP and ZK) independently extracted data. Dichotomous outcomes were analysed using risk ratios (RR) and 95% confidence intervals (CI).
Outcomes: The primary outcome was to determine the effect of M w therapy on sputum conversion. Secondary outcomes were to determine the frequency of adverse reactions.
Main Results: Three trials (four papers) involving 368 participants were included. All four papers had methodological flaws. Overall, 173 participants received M w and 168 participants received placebo or no control. M w immunotherapy was effective at reducing time to sputum conversion at days 15 (RR 2.31; 95% CI 1.75 to 3.06; P < 0.001) and 30 (RR 1.83; 95% CI 1.12 to 2.98; P = 0.02). After day 30, benefit was only demonstrated in the category II TB (re-treatment).
Conclusions: The meta-analysis suggests benefit as regards the time to sputum conversion. The available data on M w immunotherapy for participants with PTB are however methodologically flawed. We advise that M w be investigated in a well-structured, randomised controlled trial.
Export Options
About this article
Cite this article as:
Pandie Shaheen, Engel E. Mark, Kerbelker S. Zita and Mayosi M. Bongani, Mycobacterium w Immunotherapy for Treating Pulmonary Tuberculosis - a Systematic Review, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140905150215
DOI https://dx.doi.org/10.2174/1381612820666140905150215 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Identification of Active Phytochemical from Traditional Herbal Knowledge-base Targeting Pantothenate Synthetase for Anti-tuberculosis Therapy
Letters in Drug Design & Discovery Proteome Analysis of Ofloxacin and Moxifloxacin Induced Mycobacterium tuberculosis Isolates by Proteomic Approach
Protein & Peptide Letters Light Directed Gene Transfer by Photochemical Internalisation
Current Gene Therapy Spoligotyping for Identification of Pulmonary Tuberculosis with Type 2 Diabetes Mellitus Profiles in Warangal, T.S.
Anti-Infective Agents Cheminformatics Based Machine Learning Approaches for Assessing Glycolytic Pathway Antagonists of Mycobacterium tuberculosis
Combinatorial Chemistry & High Throughput Screening Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Neglected Diseases Caused By Bacterial Infections
Current Medicinal Chemistry Biospecies Capture and Detection at Low Concentration
Micro and Nanosystems Gammadelta T Lymphocytes Producing IFNγ and IL-17 in Response to Candida Albicans or Mycobacterial Antigens: Possible Implications for Acute and Chronic Inflammation
Current Medicinal Chemistry Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Brazilian Genome Sequencing Projects: State of the Art
Recent Patents on DNA & Gene Sequences Detection of Non-Tuberculosis Mycobacteria by Real Time PCR
Anti-Infective Agents A Comprehensive Review on DNA Gyrase Inhibitors
Infectious Disorders - Drug Targets Using Genomics for Natural Product Structure Elucidation
Current Topics in Medicinal Chemistry Therapeutic Implications of Gene Deletion of Ligands and Receptors of Members of TNF Superfamily
Medicinal Chemistry Reviews - Online (Discontinued) Synthesis and Antimicrobial Activity of Adamantyl Substituted Pyridoxine Derivatives
Letters in Drug Design & Discovery Mucosal Adjuvants
Current Pharmaceutical Design Recent Progress in the Identification and Development of Anti-Malarial Agents Using Virtual Screening Based Approaches
Combinatorial Chemistry & High Throughput Screening Immunoadjunctive Therapy against Bacterial Infections Using Herbal Medicines Based on Th17 Cell-mediated Protective Immunity
Current Pharmaceutical Design